Semaglutide Research Guide: The Reference GLP-1 Agonist

Every field needs a reference compound, and in incretin research that compound is semaglutide. Single-receptor selectivity plus the deepest clinical literature of any GLP-1 analogue makes it the benchmark against which dual and triple agonists are measured.

Structure and pharmacology

Semaglutide is a 31-amino-acid GLP-1 analogue with two key modifications: an amino-acid substitution protecting it from DPP-4 cleavage, and a fatty-diacid side chain that binds albumin, extending half-life dramatically. It activates the GLP-1 receptor with high selectivity — one receptor, one clean variable.

Role in comparison studies

Because tirzepatide (GLP-1+GIP) and retatrutide (GLP-1+GIP+glucagon) share design lineage with semaglutide, the three form a natural experimental ladder for isolating what each additional receptor contributes. Our GLP-1 comparison article covers the design logic in depth.

Handling

Lyophilised at -20°C; reconstitute with bacteriostatic water; solutions at 2-8°C. HPLC ≥99% verified with MS confirmation on every batch COA.

Trade note: our wholesale program supplies Australian-sourced peptides to research businesses Australia-wide, with white-label options for those building their own range.

All compounds discussed are for in-vitro laboratory research only and are not for human or veterinary use.